Viromed的PulmoPlas装置显示,有望在不伤害组织的情况下迅速治疗伊斯兰法院联盟病人的VAP。 Viromed's PulmoPlas® device shows promise in swiftly treating VAP in ICU patients without harming tissue.

Viromed Medical AG报告了其PulmoPlas装置的积极研究结果,该装置使用冷大气等离子体治疗伊斯兰法院联盟病人的通风机肺炎。 Viromed Medical AG has reported positive study results for its PulmoPlas® device, which uses cold atmospheric plasma to treat ventilator-associated pneumonia (VAP) in ICU patients. 治疗表明,在不伤害呼吸道组织的情况下,在几秒内销毁呼吸道细菌(包括呼吸系统综合症)方面非常有效。 The treatment shows high effectiveness in destroying bacteria, including MRSA, in the respiratory tract within seconds, without harming the respiratory tissues. Viromed计划申请PulmoPlas的销售许可,旨在减少VAP病例中的感染和抗生素使用。 Viromed plans to apply for marketing authorization for PulmoPlas®, aiming to reduce infections and antibiotic use in VAP cases. 全面研究结果将于2025年夏初公布。 The full study results will be published in early summer 2025.